Should terminally ill patients be given access to unapproved drugs that have completed only Phase I studies?
Yes
76% (118 votes)
No
24% (38 votes)
Total votes: 156
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Chronic Pain Is Relieved by Cell Transplantation in Lab Study
- Drug-vaccine combo better for breast cancer
- Marked for destruction: Newly developed compound triggers cancer cell death
- Orthofix International Completes Divestiture of Sports Medicine Business Unit
- ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
- More Press Releases
Featured Jobs
-
Supervisor, QC Chemistry - 3rd Shift Job
Celgene Corporation - Phoenix, AZ, US -
Biostatistician (Entry Level) - Permanent Job
Yoh - Tarrytown, NY, USA -
Senior Manager, API Development
TESARO - Waltham, MA -
Director, Quality
Sucampo Pharmaceuticals - Washington, DC -
Senior Controls Engineer Job
Celgene Corporation - Phoenix, AZ, US
Latest Commentary